New xenograft-based dressing might hit the market by summer

02/21/2012 | MedCityNews.com

Harbor Medtech is preparing to submit a request that the FDA approve its NeuvoCell wound dressing based on porcine tissue. NeuvoCell will be less expensive than similar products already on the market, requires applications only once or twice instead of every seven to 10 days, and will be appropriate to treat diabetic foot ulcers, pressure ulcers and burns, founder Jerry Mezger said.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health